The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market
The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
Zydus receives EIR for the API manufacturing facility at Ankleshwar
Enflosina is a long-acting monoclonal antibody that provides direct protection for up to 5 months
The use of Apisolex polymer excipient has been proven to increase the solubility of certain APIs by as much as 50,000-fold
Subscribe To Our Newsletter & Stay Updated
